SOLIGENIX, INC. (SNGX) Form 424B3 — Aug 7, 2026
Soligenix filed Prospectus Supplement No. 2 to register just 4,253 shares of common stock underlying previously issued common warrants — a de minimis takedown — but the supplement also incorporates the company's Q2 2026 Form 10-Q, which discloses that conditions raise substantial doubt about the company's ability to continue as a going concern. The 10-Q confirms the Board terminated the HyBryte development program for cutaneous T-cell lymphoma in June 2026 after the Phase 3 FLASH2 trial was recommended to halt for futility at its April 2026 interim analysis, with approximately $70,000 in estimated wind-down charges and the related $1.1 million FDA grant study also wound down.
Key figures
- Eps
- -0.12 (Q2 2026); -0.37 (H1 2026)
- Revenue
- 0
- Net Income
- -1,987,354 (Q2 2026); -4,812,319 (H1 2026)
- Total Assets
- 10499470
- Cash Position
- 9811141
- Shares Outstanding
- 21765479
- Cash runway
- into the second quarter of 2028
- Working capital
- 6499947
- Total liabilities
- 3853913
- Accumulated deficit
- 249863451
- Atm shares sold h1 2026
- 11538661
- Warrant shares registered
- 4253
- Atm gross proceeds h1 2026
- 6037818
- July 2026 atm shares issued
- 128000
- Weighted avg shares q2 2026
- 15951949
- Fda orphan grant subcontract
- $1.1 million
- Atm weighted avg price h1 2026
- $0.54
- Nasdaq bid price cure deadline
- December 7, 2026
- Cash used in operations h1 2026
- 4064414
- Hybryte wind down charges estimate
- $70,000
- Atm remaining capacity july 31 2026
- $2.4 million
- July 2026 atm weighted avg fair value
- $0.40
- Atm cumulative sales through june 30 2026
- $6,234,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.